S100A8 is a prognostic signature and associated with immune response in diffuse large B-cell lymphoma.
Saved in:
| Title: | S100A8 is a prognostic signature and associated with immune response in diffuse large B-cell lymphoma. |
|---|---|
| Authors: | Lin Q; Department of Pharmacy, The Affiliated Hospital of Putian University, Putian, Fujian, China.; Pharmaceutical and Medical Technology College, Putian University, Putian, Fujian, China., Su J; Pharmaceutical and Medical Technology College, Putian University, Putian, Fujian, China., Fang Y; Pharmaceutical and Medical Technology College, Putian University, Putian, Fujian, China., Zhong Z; Pharmaceutical and Medical Technology College, Putian University, Putian, Fujian, China., Chen J; Pharmaceutical and Medical Technology College, Putian University, Putian, Fujian, China., Zhang C; Department of Hematology and Rheumatology, the Affiliated Hospital of Putian University, Putian, Fujian, China. |
| Source: | Frontiers in oncology [Front Oncol] 2024 Feb 01; Vol. 14, pp. 1344669. Date of Electronic Publication: 2024 Feb 01 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
